May 14, 2020 / 03:00PM GMT
Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity Research
Good day, everybody. My name is Jason Gerberry. I cover smid-cap biotech and especially pharmaceutical for Bank of America. I'm pleased to be introducing our next company presenter, FibroGen and new CEO, Enrique Conterno. FibroGen is -- most would know the company for its development of roxadustat for anemia associated with dialysis or renal disease, but the company also has an emerging early to mid-stage pipeline with pamrevlumab for fibrotic disorders.
So Enrique, first off, thanks for joining us at the conference on a virtual basis.
Enrique A. Conterno - FibroGen, Inc. - CEO & Director
No, thank you, Jason. It's a pleasure for me to be here and talk about the progress we're making at FibroGen.
Questions and Answers:
Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity ResearchGreat. I mean, look, you're no longer new to the role, but I imagine that the opportunity with
Trustpilot
